Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 9/20 | 0.74 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.64 |
| ▸ | RAF1 | P04049 | 6/20 | 0.64 |
| ▸ | BRAF | P15056 | 5/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.64 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.63 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.63 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.63 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.63 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.63 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.63 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.63 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.63 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.63 |
| ▸ | MET | P08581 | 2/20 | 0.62 |
| ▸ | PLK4 | O00444 | 2/20 | 0.61 |
| ▸ | AURKA | O14965 | 2/20 | 0.61 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12391532 | 0.89 | RAF1 (0.76) | KDRMAPK14RAF1BRAFEPHX2 | |
| SCHEMBL29834896 | 0.88 | KDR (0.62) | KDRMAPK14RAF1BRAFEPHX2 | |
| SCHEMBL27173866 | 0.88 | KDR (0.62) | KDRMAPK14RAF1BRAFEPHX2 | |
| SCHEMBL3653979 | 0.88 | RAF1 (0.69) | KDRMAPK14RAF1BRAFEPHX2 | |
| SCHEMBL14684309 | 0.86 | KDR (0.81) | KDRMAPK14RAF1BRAFEPHX2 | |
| SCHEMBL257980 | 0.86 | RAF1 (0.82) | KDRMAPK14RAF1BRAFEPHX2 | |
| SCHEMBL3644017 | 0.86 | RAF1 (0.62) | KDRMAPK14RAF1BRAFEPHX2 | |
| SCHEMBL18681347 | 0.86 | BRAF (0.70) | KDRMAPK14RAF1BRAFEPHX2 | |
| SCHEMBL13004737 | 0.85 | RAF1 (0.69) | KDRMAPK14RAF1BRAFEPHX2 | |
| SCHEMBL19878581 | 0.85 | KDR (1.00) | KDRMAPK14RAF1BRAFEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3500257-B1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2025-07-02 | — | — | EP | disclosed |
| US-11066370-B2 | Kinase inhibitor compounds, compositions, and methods of treating cancer | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2021-07-20 | — | — | US | disclosed |
| US-11066370-B2 | Kinase inhibitor compounds, compositions, and methods of treating cancer | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2021-07-20 | — | — | US | disclosed |
| US-20200325103-A1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2020-10-15 | — | — | US | disclosed |
| US-20200325103-A1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2020-10-15 | — | — | US | disclosed |
| US-10519113-B2 | Kinase inhibitor compounds, compositions, and methods of treating cancer | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-12-31 | — | — | US | disclosed |
| US-10519113-B2 | Kinase inhibitor compounds, compositions, and methods of treating cancer | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-12-31 | — | — | US | disclosed |
| US-20190202789-A1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | ICHAN SCHOOL OF MEDICINE AT MOUNT SINAL (US) | 2019-07-04 | — | — | US | disclosed |
| US-20190202789-A1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | ICHAN SCHOOL OF MEDICINE AT MOUNT SINAL (US) | 2019-07-04 | — | — | US | disclosed |
| EP-3500257-A1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | Icahn School of Medicine at Mount Sinai (US) | 2019-06-26 | — | — | EP | disclosed |
| WO-2018035346-A1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | ICHAN SCHOOL OF MEDICINE AT MOUNT SINAL (US) | 2018-02-22 | — | — | WO | disclosed |
| WO-2018035346-A1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | ICHAN SCHOOL OF MEDICINE AT MOUNT SINAL (US) | 2018-02-22 | — | — | WO | disclosed |
| CN-102266290-B | 4-(4-benzamido-phenoxyl)-2-(methyl-carbamyl) pyridine derivative or solid dispersion of salt derivative, as well as preparation method of derivative or solid dispersion | UNIV SICHUAN | 2013-11-13 | — | — | CN | disclosed |
| CN-102266290-B | 4-(4-benzamido-phenoxyl)-2-(methyl-carbamyl) pyridine derivative or solid dispersion of salt derivative, as well as preparation method of derivative or solid dispersion | UNIV SICHUAN | 2013-11-13 | — | — | CN | disclosed |
| CN-102266290-A | 4-(4-benzamido-phenoxyl)-2-(methyl-carbamyl) pyridine derivative or solid dispersion of salt derivative, as well as preparation method of derivative or solid dispersion | — | 2011-12-07 | — | — | CN | disclosed |
| CN-102266290-A | 4-(4-benzamido-phenoxyl)-2-(methyl-carbamyl) pyridine derivative or solid dispersion of salt derivative, as well as preparation method of derivative or solid dispersion | — | 2011-12-07 | — | — | CN | disclosed |
| CN-101362718-B | 4-(4-benzamido phenoxy)-2-(methylcarbamoyl) pyridine derivatives, preparation method and application thereof | UNIV SICHUAN | 2010-12-08 | — | — | CN | disclosed |
| CN-101362718-B | 4-(4-benzamido phenoxy)-2-(methylcarbamoyl) pyridine derivatives, preparation method and application thereof | UNIV SICHUAN | 2010-12-08 | — | — | CN | disclosed |
| CN-101362718-A | 4-(4-benzamido phenoxy)-2-(methylcarbamoyl) pyridine derivatives, preparation method and application thereof | UNIV SICHUAN (CN) | 2009-02-11 | — | — | CN | disclosed |
| CN-101362718-A | 4-(4-benzamido phenoxy)-2-(methylcarbamoyl) pyridine derivatives, preparation method and application thereof | UNIV SICHUAN (CN) | 2009-02-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325103-A1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | MAP3K1, KSR1, MAP3K11 | KDR 706/4885MAPK14 235/4885RAF1 16/4885 |
| US-10519113-B2 | Kinase inhibitor compounds, compositions, and methods of treating cancer | MAP3K1, KSR1, MAP3K11 | KDR 706/4885MAPK14 235/4885RAF1 16/4885 |
| US-11066370-B2 | Kinase inhibitor compounds, compositions, and methods of treating cancer | MAP3K1, KSR1, MAP3K11 | KDR 706/4885MAPK14 235/4885RAF1 16/4885 |
| US-20190202789-A1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | MAP3K1, KSR1, MAP3K11 | KDR 706/4885MAPK14 235/4885RAF1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.